Hormonal Therapies for Acne in Females
For hormonally driven acne in adolescent or adult females, combined oral contraceptives (COCs) and spironolactone receive conditional recommendations as effective treatment options, with topical clascoterone available for both genders when targeting androgens locally 1.
Primary Hormonal Treatment Options
The 2024 AAD guidelines establish three main hormonal therapies for acne management 1:
Combined Oral Contraceptives (COCs)
- Conditional recommendation for use in acne treatment
- Different brands and dosing regimens show generally similar efficacy 2
- Significantly reduce lesion counts across all lesion types compared to placebo 3
- No consistent efficacy differences between different COC formulations 3
Key Safety Consideration: COC users have 3-times increased odds of venous thromboembolism versus non-users (95% CI 2.46-2.59) 3. Screen for VTE risk factors before prescribing. However, these medications provide measurable protection against endometrial and ovarian cancer 3.
Spironolactone
- Conditional recommendation as an effective acne treatment 1
- Recent clinical trial data supports its use as a first-line treatment for women with acne 2
- Good tolerability profile with effective results 3
Critical Practice Point: Potassium monitoring is of low value for patients on spironolactone unless specific risk factors for hyperkalemia exist 2. This represents an important shift from historical practice patterns.
Topical Clascoterone
- Conditional recommendation for use 1
- Safe and effective topical anti-androgen for both men and women 2
- Limited systemic effects on reproductive hormones 2
- Targets hormones locally without systemic hormonal manipulation 4
Treatment Algorithm
For females with hormonally driven acne:
First-line consideration: Either COCs (if contraception desired/appropriate) or spironolactone based on:
- Patient's contraceptive needs
- VTE risk factors (for COCs)
- Comorbidity profile
- Patient preference
- Access and cost 2
Alternative/adjunctive: Topical clascoterone for localized hormonal targeting without systemic effects
Combination approach: Hormonal therapies should be combined with topical therapies using multiple mechanisms of action (benzoyl peroxide, retinoids) as recommended by good practice statements 1
Important Clinical Nuances
Antibiotic Stewardship Context: With growing concerns about antibiotic resistance and the AAD's emphasis on limiting systemic antibiotic use 1, hormonal therapies represent an increasingly important alternative strategy that should be more widely incorporated into acne treatment 2, 5.
Gender Considerations: While COCs and spironolactone are female-specific, clascoterone provides the first hormonal option suitable for males 2, 4.
Timing Expectations: Hormonal therapies typically require 3-6 months to show full effect. Patients need counseling on this timeline to maintain adherence.
Common Pitfalls to Avoid
- Over-monitoring potassium on spironolactone in healthy patients without risk factors 2
- Failing to screen for VTE risk before prescribing COCs 3
- Using hormonal therapy as monotherapy instead of combining with topical agents as recommended 1
- Delaying hormonal therapy in appropriate candidates due to antibiotic preference, when guidelines emphasize limiting antibiotic duration 1